2025-522189-60-00
Recruiting
Phase 2
Cityview: PET-Based Imaging to Evaluate the Distribution of Radiolabeled CIT-013 in Patients with Inflammatory Mediated Immune Disease
Citryll B.V.1 site in 1 country12 target enrollmentStarted: October 24, 2025Last updated:
Overview
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Citryll B.V.
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- This objective is measured by whole body PET-CT imaging 24 hours (D2) after IP administration. In addition to visual assessment, uptake of [89Zr]-DFO-CIT-013 will be quantified per organ(-system). In vivo distribution profiles will be evaluated per cohort to determine ranges of uptake per organ(-system) and between cohorts to compare uptake in different IMIDs.
Overview
Brief Summary
The primary objective of this trial is to evaluate the distribution of radiolabeled CIT-013 in patients with IMIDs.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •For male participants with female partners of child-bearing potential, an adequate form of contraception must be adhered to, and men must refrain from donating sperm, prior to entry into the trial and for a further 6 months after IP administration.
- •Willing and able to provide written, informed consent.
- •(RA specific) Diagnosed with RA according to the 2010 classification criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) ≥ 6 months prior to screening (diagnosis based on medical records).
- •(active RA specific) Disease Activity Score 28 (DAS28) C-Reactive Protein (CRP) (DAS28-CRP) ≥ 4.2 AND ≥ 1 Swollen Joint AND ≥ 1 Tender Joint at screening.
- •(RA in remission specific) DAS28-CRP score ≤ 2.6 AND no Swollen Joints or Tender Joints at screening.
- •(HS specific) HS of ≥ 6 months duration (diagnosis based on medical records).
- •(HS specific) International Hidradenitis Suppurativa Severity Score System (IHS4) score of ≥ 7 AND at least 1 draining tunnel at screening.
- •Female (of non-childbearing potential) or male between 60-85 years of age (inclusive).
Exclusion Criteria
- •Known history of severe allergies, non-allergic drug reactions, or multiple drug allergies.
- •Active HBV, HCV, or HIV infection, as tested and confirmed during screening.
- •Evidence of active TB or being at high risk for TB, assessed according to local site procedures.
- •Male participants with a pregnant partner.
- •Known hypersensitivity to any of the ingredients (L-histidine, Histidine-HCl monohydrate, Sucrose, Polysorbate) of the IP, including the radioactive tracer, or to drugs of similar chemical structure or pharmacological profile.
- •Significant clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, at discretion of the Investigator (or designee).
- •Any other multi-system autoimmune disease.
- •Any other condition which, in the Investigator’s opinion, will interfere with the trial.
- •Female participants of childbearing potential (including females that are pregnant or breastfeeding). Follicle-stimulating hormone (FSH) levels < 50 IU/L are exclusionary, unless there is a confirmed other reason for non-childbearing potential (e.g., complete hysterectomy), at discretion of the Investigator.
- •A recent (within 2 years) history of drug and/or alcohol abuse.
Outcomes
Primary Outcomes
This objective is measured by whole body PET-CT imaging 24 hours (D2) after IP administration. In addition to visual assessment, uptake of [89Zr]-DFO-CIT-013 will be quantified per organ(-system). In vivo distribution profiles will be evaluated per cohort to determine ranges of uptake per organ(-system) and between cohorts to compare uptake in different IMIDs.
This objective is measured by whole body PET-CT imaging 24 hours (D2) after IP administration. In addition to visual assessment, uptake of [89Zr]-DFO-CIT-013 will be quantified per organ(-system). In vivo distribution profiles will be evaluated per cohort to determine ranges of uptake per organ(-system) and between cohorts to compare uptake in different IMIDs.
Secondary Outcomes
- Frequency and severity of treatment-emergent adverse events (TEAE) throughout the trial period, including clinically relevant findings and ADAs.
- Pharmacokinetic (PK) levels throughout the trial, per cohort.
Investigators
Maarten Kraan
Scientific
Citryll B.V.
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 2
Proof of Concept trial with CIT-013 in Rheumatoid Arthritis2024-517356-35-00Citryll B.V.77
Not yet recruiting
Not Applicable
The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE TrialNCT07257718Chiti Arturo262
Not yet recruiting
Phase 1
A Positron Emission Tomography (PET) study to examine the properties of
a novel radioligand's suitability for imaging mutant huntingtin2024-515786-34-02CHDI Foundation Inc.27
Not yet recruiting
Phase 2
[68Ga]Ga-FAPI PET/CT for response evaluation during immune checkpoint inhibitor therapy in malignant melanoma2023-509549-11-00Rigshospitalet20
Withdrawn
Phase 2
[68Ga]Ga-FAPI total body PET/CT for improving diagnostic sensitivity and preoperative staging in gastroesophageal cancer and pancreatic cancer2023-503632-41-00Rigshospitalet60